Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmonary fibrosis

Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmonary fibrosis

May 22, 2018 Treatment with PBI-4050 for 12 weeks positively affected biomarkers known to have antifibrotic activity New clinical data presented at the American Thoracic Society 2018 International Conference LAVAL, QC, May 22, 2018 /PRNewswire/ – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)